News
Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...
Fifty 1 Labs (OTC: FITY) , through its subsidiary Fifty1 AI Labs, LLC, announced the successful completion of the REVIVE Adaptive Platform Trial (NCT ...
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best and Safe Dividend Stocks to Buy Now. Bristol-Myers Squibb Company (NYSE:BMY) presents a strong case for investors looking for both ...
Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the ...
Explore more
US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...
(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...
The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a ...
BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...
The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results